Investor Relations

About Theravance Biopharma


Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference® in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension, has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in multiple system atrophy patients. The Company is committed to creating/driving shareholder value.

Corporate Presentation

May 2024 Investor Presentation

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events & Presentations
05/23/24 at 10:00 AM EDT
Virtual KOL Event to Discuss Ampreloxetine’s Potential for the Treatment of Symptomatic nOH in Patients with MSA
05/20/24 at 11:30 AM EDT
H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Shareholder Tools